 CARLSBAD, Calif.--BUSINESS WIRE--- LCTX AMD--Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1, its oligodendrocyte progenitor cell OPC allogeneic transplant for the treatment of acute spinal cord injuries SCI. The Company reported it has developed an enhanced differentiation process, leading to major improvements in production and quality of its OPC1 cel 